Clinical and laboratory characteristics of study AML (n = 33) and MDS (n = 22) patients
Characteristic . | Median . |
|---|---|
| AML patients | |
| Age, y (range) | 64 (23-76) |
| WBC count, × 109/L (range) | 2.3 (1.0-49.1) |
| Hemoglobin level, g/L (range) | 98 (73-171) |
| Platelets, × 109/L (range) | 30 (6-283) |
| % Peripheral blood blasts (range) | 14 (1-75) |
| % Bone marrow blasts (range) | 42 (0-90) |
| Bone marrow cellularity | |
| Hypocellular, less than 20% | 7 |
| Normocellular, 20% to 50% | 9 |
| Hypercellular, more than 50% | 17 |
| LDH, IU/L (range) | 461 (94-6763) |
| Creatinine, μM (range) | 88.4 (17.68-167.96) |
| Bilirubin, μM (range) | 8.55 (1.71-20.52) |
| SGPT, IU/L (range) | 20 (2-101) |
| Albumin, g/L (range) | 35 (18-44) |
| Male/female (%) | 20/13 (61/39) |
| Performance status, % | |
| 0/1 | 5/18 (15/55) |
| 2 | 10 (30) |
| Prior MDS (%) | 10 (30) |
| Primary refractory (%) | 10 (30) |
| Relapsed with CR duration, less than 1 y (%) | 12 (36) |
| Relapsed with CR duration, 1 y or longer (%) | 11 (33) |
| CR1 duration, mo, median (range) | 6 (1-36) |
| No. of prior salvage regimens, % | |
| None | 7 |
| 1 | 12 |
| 2 to 3 | 14 |
| MDS patients | |
| Age, y (range) | 66 (22-80) |
| WBC count, × 109/L (range) | 2.5 (0.4-5.7) |
| Hemoglobin level, g/L (range) | 89 (69-114) |
| Platelets, × 109/L (range) | 29 (3-540) |
| % Peripheral blood blasts (range) | 1 (0-27) |
| % Bone marrow blasts (range) | 6 (0-29) |
| Bone marrow cellularity | |
| Hypocellular, less than 20% | 4 |
| Normocellular, 20% to 50% | 17 |
| Hypercellular, more than 50% | 1 |
| LDH, IU/L (range) | 342 (117-2526) |
| Creatinine, μM (range) | 70.72 (44.2-114.92) |
| Bilirubin, μM (range) | 11.97 (5.13-34.2) |
| SGPT, IU/L (range) | 29 (6-108) |
| Albumin, g/L (range) | 36 (21-48) |
| Male/female (%) | 13/9 (59/41) |
| Performance status (%) | |
| 0/1 | 4/12 (18/55) |
| 2 | 6 (27) |
| Diagnoses | |
| RAEBT | 8 |
| RAEB | 14 |
| No. of prior regimens, % | |
| None | 7 |
| 1 | 7 |
| 2-3 | 8 |
| Median (range) | 1 (0-3) |
Characteristic . | Median . |
|---|---|
| AML patients | |
| Age, y (range) | 64 (23-76) |
| WBC count, × 109/L (range) | 2.3 (1.0-49.1) |
| Hemoglobin level, g/L (range) | 98 (73-171) |
| Platelets, × 109/L (range) | 30 (6-283) |
| % Peripheral blood blasts (range) | 14 (1-75) |
| % Bone marrow blasts (range) | 42 (0-90) |
| Bone marrow cellularity | |
| Hypocellular, less than 20% | 7 |
| Normocellular, 20% to 50% | 9 |
| Hypercellular, more than 50% | 17 |
| LDH, IU/L (range) | 461 (94-6763) |
| Creatinine, μM (range) | 88.4 (17.68-167.96) |
| Bilirubin, μM (range) | 8.55 (1.71-20.52) |
| SGPT, IU/L (range) | 20 (2-101) |
| Albumin, g/L (range) | 35 (18-44) |
| Male/female (%) | 20/13 (61/39) |
| Performance status, % | |
| 0/1 | 5/18 (15/55) |
| 2 | 10 (30) |
| Prior MDS (%) | 10 (30) |
| Primary refractory (%) | 10 (30) |
| Relapsed with CR duration, less than 1 y (%) | 12 (36) |
| Relapsed with CR duration, 1 y or longer (%) | 11 (33) |
| CR1 duration, mo, median (range) | 6 (1-36) |
| No. of prior salvage regimens, % | |
| None | 7 |
| 1 | 12 |
| 2 to 3 | 14 |
| MDS patients | |
| Age, y (range) | 66 (22-80) |
| WBC count, × 109/L (range) | 2.5 (0.4-5.7) |
| Hemoglobin level, g/L (range) | 89 (69-114) |
| Platelets, × 109/L (range) | 29 (3-540) |
| % Peripheral blood blasts (range) | 1 (0-27) |
| % Bone marrow blasts (range) | 6 (0-29) |
| Bone marrow cellularity | |
| Hypocellular, less than 20% | 4 |
| Normocellular, 20% to 50% | 17 |
| Hypercellular, more than 50% | 1 |
| LDH, IU/L (range) | 342 (117-2526) |
| Creatinine, μM (range) | 70.72 (44.2-114.92) |
| Bilirubin, μM (range) | 11.97 (5.13-34.2) |
| SGPT, IU/L (range) | 29 (6-108) |
| Albumin, g/L (range) | 36 (21-48) |
| Male/female (%) | 13/9 (59/41) |
| Performance status (%) | |
| 0/1 | 4/12 (18/55) |
| 2 | 6 (27) |
| Diagnoses | |
| RAEBT | 8 |
| RAEB | 14 |
| No. of prior regimens, % | |
| None | 7 |
| 1 | 7 |
| 2-3 | 8 |
| Median (range) | 1 (0-3) |
WBC indicates white blood cell; LDH, lactate dehydrogenase; and SGPT, serum glutamic pyruvic-transaminase